Article
Acute leukemia and myelodysplasia in polycythemia vera. A clinical study with long-term follow-up
Article first published online: 29 JUN 2006
DOI: 10.1002/1097-0142(19880101)61:1<89::AID-CNCR2820610115>3.0.CO;2-0
Copyright © 1988 American Cancer Society
Additional Information
How to Cite
Najean, Y., Rain, J. D., Arrago, J. P., Deschamps, A., Dresch, C. and Daniel, M. T. (1988), Acute leukemia and myelodysplasia in polycythemia vera. A clinical study with long-term follow-up. Cancer, 61: 89–95. doi: 10.1002/1097-0142(19880101)61:1<89::AID-CNCR2820610115>3.0.CO;2-0
Publication History
- Issue published online: 29 JUN 2006
- Article first published online: 29 JUN 2006
- Manuscript Accepted: 8 JUL 1987
- Abstract
- References
- Cited By
Abstract
The analysis of 288 cases of polycythemia vera (PV) with a minimal follow-up of 10 years enabled us to study the characteristics of acute leukemia as observed in 33 patients (11.4%). In 50% of the patients (16 of 33), the malignant transformation is of the refractory anemia with excess of blasts (RAEB) type. Half of these further transform to acute nonlymphocytic leukemia (ANLL). Their life expectancy is not better than patients who abruptly develop ANLL. Leukemic transformation shows a frequency peak in the eighth year after initial evaluation in PV treated with chemotherapy and in the 11th year in patients treated with radiotherapy. In 30% of the patients myelofibrosis, or the spent phase of PV, is present before the transformation to acute leukemia (AL). This complication is, however, part of the natural history of PV and is observed in 20% of PV patients at 10 years when leukemic transformation is absent. Marrow fibrosis can therefore not be considered as a preleukemic phase. It was also noted that the occurrence of myeloid metaplasia/myelofibrosis is more frequent and begins earlier in patients treated by phlebotomy alone, and who do not transform to leukemia. The clinical characteristics of these AL, including high frequency of partial marrow invasion, difficulties in cytologic classification, a peak incidence similar to that in patients treated by chemotherapy or radiotherapy for a prior malignancy, multiple chromosome abnormalities, and poor response to therapy are all highly suggestive of secondary leukemias.

1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470)